Access Statistics for Martina Garau

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Access Mechanisms for Orphan Drugs: A Comparative Study of Selected European Countries 0 0 0 3 2 2 9 19
Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders' Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL) 0 0 0 1 1 1 44 52
Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence 0 0 3 18 0 3 13 41
Are Cost-Effectiveness Thresholds fit for Purpose for Real-World Decision Making? 0 1 5 5 0 1 10 10
Assessment and Appraisal of Oncology Medicines: NICE's Approach and International HTA Experience 0 0 0 2 1 2 7 9
Assessment of the Impact of Orphan Medicinal Products on the European Economy and Society 0 0 0 2 1 3 6 11
Can and Should Value Based Pricing Be Applied to Molecular Diagnostics? 0 1 2 2 0 2 6 19
Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries 0 0 3 20 2 11 23 43
Donor Investment Choices: Modeling the Value for Money of Investing in Product Development, Public Private Parnerships as Compared to Other Health Care and Non-Health Care Interventions 0 0 0 1 1 1 3 6
Estimating Pharmaceutical Companies' Value to the Nation: Case Study of the British Pharma Group 0 0 1 2 3 4 6 10
Exploring the Interdependencies of Research Funders in the UK 0 0 0 0 0 0 4 5
Exploring the Interdependency between Public and Charitable Medical Research 0 0 0 2 2 3 9 16
Exploring the link between health and wealth in decision making 0 0 0 3 0 2 8 17
How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy 0 1 3 18 1 4 14 26
Improving Efficiency and Resource Allocation in Future Cancer Care 1 3 6 18 2 12 45 80
International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making 1 32 32 32 4 22 22 22
Multi-Criteria Decision Analysis to Value Orphan Medicines 0 0 0 0 0 1 7 8
Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward 0 0 1 5 0 1 25 38
Obstructive Sleep Apnoea: Health Economics Report 0 0 3 3 0 0 11 17
Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution? 0 0 2 2 1 1 5 8
Policy Options for Formulary Development in Middle-income Countries 0 0 1 1 3 3 10 15
Policy Options for Formulary Development in Middle-income Countries: Mexico Case Study 0 0 0 2 1 2 7 15
R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C 0 0 1 19 3 6 27 75
Unrelieved Pain in Palliative Care in England 0 0 2 2 0 0 16 16
Using QALYs in Cancer: Review of the Methodological Limitations 0 0 0 1 0 0 2 9
Total Working Papers 2 38 65 164 28 87 339 587


Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL) 0 0 0 0 0 1 7 32
Total Journal Articles 0 0 0 0 0 1 7 32


Book File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
European Medicines Pricing and Reimbursement: Now and the Future 0 0 0 5 0 0 2 13
Total Books 0 0 0 5 0 0 2 13


Statistics updated 2020-09-04